Ranibizumab
Title: Ranibizumab
CAS Registry Number: 347396-82-1
CAS Name: Anti-(human vascular endothelial growth factor) immunoglobulin G1 Fab fragment (human-mouse monoclonal rhuFAB V2 g1-chain) disulfide with human-mouse monoclonal rhuFAB V2 light chain
Additional Names: rhuFabV2
Trademarks: Lucentis (Genentech)
Literature References: Recombinant humanized monoclonal antibody fragment directed against VEGF; approx 48 kDa. Exhibits antiangiogenic activity. Prepn: M. Baca et al., WO 9845331; eidem, US 6884879 (1998, 2005 both to Genentech). Intraocular biodistribution study: J. Mordenti et al., Toxicol. Pathol. 27, 536 (1999). In vivo efficacy vs choroid neovascularization: M. G. Krzystolik et al., Arch. Ophthalmol. 120, 338 (2002); in combination with verteporfin: D Husain et al., ibid. 123, 509 (2005). Pharmacokinetics: J. Gaudreault et al., Invest. Ophthalmol. Visual Sci. 46, 726 (2005). Clinical evaluation: J. S. Heier et al., Ophthalmology 113, 633 (2006).
Therap-Cat: Treatment of age-related macular degeneration.
Keywords: Macular Degeneration Treatment.

Others monographs:
Gum TragacanthEdatrexateEthyl TartrateZirconium Hydride
CaramelLead BromideStrontium FormateCollagenase
AnthramycinFerric Ammonium CitrateThioxantheneCaproic Aldehyde
HydroxyphenamatePotassium Tellurate(VI)Potassium Hexafluoromanganate(IV)Tridiphane
©2016 DrugLead US FDA&EMEA